Hope S. Rugo, MD, FASCO, is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California, San Francisco in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.
Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer, and has published widely in this area. Her current research interests include immunotherapy and combinations of targeted agents in the treatment of breast cancer to overcome resistance. In addition, Dr. Rugo has conducted a number of studies focusing on reducing toxicity from therapy, resulting in approval of scalp cooling to reduce chemotherapy-induced hair loss, and a steroid mouthwash to reduce targeted agent stomatitis. She is an investigator and the chair of the Safety Committee for the multicenter adaptively randomized phase II I-SPY2 trial, and also serves on the Novel Agents Committee. Dr. Rugo is the co-chair of the Triple Negative Working Group and an active member of the Translational Breast Cancer Research Consortium (TBCRC), and is the principal investigator of several TBCRC trials including a multi-center immunotherapy trial funded by the Breast Cancer Research Foundation (BCRF). She is an active member of the Alliance (formerly CALGB) Breast Committee, as well as ASCO, where she serves on the Guidelines Committee and as an editor for the Education Committee.
In addition to her research, Dr. Rugo is an active clinician, and is committed to education, regularly lecturing locally, nationally, and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the Bay Area.
Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California, San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Giannini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.
Christi Shawis Senior Vice President of Eli Lilly and Company and President of Lilly Bio-Medicines. Before she rejoined Lilly in April 2017, she had most recently served as US Head and President of Novartis Corporation.
Ms. Shaw serves as a board member of the Biotechnology Industry Organization (BIO) and as an advisor to the Healthcare Businesswomen’s Association. In 2018, she was honored with the Health Industry Visionary Award by the Society for Women’s Health Research. In May 2016, she was presented with Eye for Pharma’s prestigious Lifetime Achievement Award for her industry thought leadership and dedication to the needs of patients. Also in 2016, PharmaVOICE named Ms. Shaw to its 100 Most Inspiring People list, and Diversity Journal included her on its roster of Women Worth Watching. She has spoken at leading industry conferences on topics ranging from the importance of driving innovation to support better patient outcomes and the value of encouraging a diverse and inclusive professional culture. Her perspectives have been featured in Working Mother and Life Science Leader magazines.
Ms. Shaw earned a Bachelor of Business Administration from Iowa State University and an MBA from the University of Wisconsin. She worked at Lilly from 1989 to 2002 in sales and marketing roles, and she later held a series of increasingly senior positions in the Janssen and Ethicon subsidiaries of Johnson & Johnson.
In 2017, Ms. Shaw, inspired by the hardships endured by her late mother and sister, founded the More Moments More Memories Foundation to assist cancer patients and their caregivers.
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris Professor and Chief of the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha, Nebraska. In addition, she is a past president of the American Society of Clinical Oncology.
Dr. Vose received her medical degree, completed her residency in internal medicine as chief resident, and completed a fellowship in hematology and oncology at the University of Nebraska Medical Center. In addition, she completed a sabbatical at Stanford University, and continued her education by obtaining an MBA in Health Administration from the University of Colorado Business School.
Dr. Vose has focused her career on translational research improving the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma by developing a focused translational research program evaluating novel therapies, such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway-directed agents, stem cell transplantation, and CAR T-cell therapy. Further, her funding record and publications in NHL therapy and transplantation research have substantially added to the research and knowledge base for lymphoma therapy. As a result of her NHL research, Dr. Vose has been recognized nationally and internationally through worldwide research awards and invited lectureships.